United Therapeutics Hits New 52-Week High Following Analyst Upgrade (UTHR)
United Therapeutics (NASDAQ:UTHR) hit a new 52-week high during trading on Friday after Wedbush raised their price target on the stock from $133.00 to $141.00, American Banking & Market News reports. Wedbush currently has an outperform rating on the stock. United Therapeutics traded as high as $118.00 and last traded at $116.00, with a volume of 3,991,918 shares changing hands. The stock had previously closed at $91.69.
A number of other firms have also recently commented on UTHR. Analysts at Standpoint Research raised their price target on shares of United Therapeutics from $118.00 to $140.00 in a research note on Friday. They now have a “buy” rating on the stock. Separately, analysts at Zacks upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Thursday, August 21st. They now have a $112.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday, July 31st. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. United Therapeutics currently has an average rating of “Buy” and a consensus target price of $104.87.
In other United Therapeutics news, CFO John Maxim Ferrari sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $93.75, for a total transaction of $937,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
The stock has a 50-day moving average of $91.63 and a 200-day moving average of $95.41. The company has a market cap of $5.496 billion and a price-to-earnings ratio of 17.72.
United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, July 29th. The company reported $2.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter last year, the company posted $1.52 earnings per share. United Therapeutics’s revenue was up 15.0% compared to the same quarter last year. Analysts expect that United Therapeutics will post $8.55 EPS for the current fiscal year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Receive News & Ratings for United Therapeutics Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co and related companies with Analyst Ratings Network's FREE daily email newsletter.